Single-use Bioprocessing Market Size, Share & Trends Analysis Report By Product (Work Equipment, Apparatus & Plants), By Workflow (Upstream, Downstream), By End-use, By Region, And Segment Forecasts, 2023 - 2030

Report Overview

The global single-use bioprocessing market size was valued at USD 23,433.3 million in 2022 and is anticipated to expand at a compound annual growth rate (CAGR) of 16.24% from 2023 to 2030. The adoption of single-use bioprocessing technology is driven by the growing demand for biopharmaceuticals over the past few years, along with an increase in investments for the development of biologics, such as monoclonal antibodies, vaccines, recombinant proteins, and others. Furthermore, benefits pertaining to the use of single-use technology, such as significant reduction in costs and time required for operations & facility construction have supported the implementation of single-use systems in the bioprocessing sector.

The COVID-19 pandemic has generated new growth opportunities for key stakeholders in the industry. Key biopharmaceutical players can leverage the opportunity by expanding their COVID-19-related product offerings by scaling up their production facilities with the implementation of single-use bioprocessing equipment. A significant number of biopharmaceutical companies are actively involved in the development & production of COVID-19 vaccines. These programs are majorly based on single-use technologies as these systems are flexible, cost-effective, and reduce the risk of cross-contamination.

Such an ongoing and continuous increase in the adoption of these bioprocessing systems due to the COVID-19 pandemic is anticipated to drive industry growth. The commercial success of biopharmaceuticals has led single-use manufacturers to expand their production facilities globally. Capacity expansion projects have been a part of many manufacturers’ multi-year plans, to leverage a global reach and a broader customer base. For instance, in December 2020, Merck KGaA invested over USD 42 million to broaden its existing manufacturing facilities in Danvers, Massachusetts, and Jaffrey, New Hampshire, U.S.

This expansion was aimed at enhancing the company’s single-use assembly operations along with other product portfolios. Furthermore, with the rising focus on the development of regenerative medicine, such as cell and gene therapies, increased success of clinical trials, and enhanced rate of regulatory approvals, demand for commercialization of these products is expected to grow in the near future. In addition, owing to the increasing outsourcing activities in biopharmaceutical manufacturing, CMOs are adopting single-use systems for maintaining highly dynamic and frequently changing product portfolios.

Consequently, the extensive implementation of single-use systems in CMOs across the globe is likely to boost industry growth. For instance, in July 2021, Pall Corp. signed a contract with Exothera S.A., a CDMO, to establish a manufacturing space using Allegro STR single-use bioreactors and other technologies. Although innovations in single-use technology are the current trend for the bioprocessing industry, the technology has still not completely displaced stainless steel reusable systems. High-volume biopharmaceutical product manufacturers continue to fixate on the multi-use system due to their feasibility at large scales. This represents a significant challenge for the industry's growth.

Product Insights

The simple & peripheral elements segment recorded the largest market share of 49.1% in 2022 due to continuous innovations in these products and increasing prominence of bioprocessing operations in overall manufacturing process. Tubing, filters, connectors, and transfer systems held a majority share within simple & peripheral elements as tubing and connectors are provided by most single-use suppliers in a compatible format with single-use bags, bioreactors, or other single-use bioprocessing apparatus. For instance, Thermo Fisher Scientific, Inc. offers customization options to add tubing and connectors to its bioprocessing container bags and other bioprocessing equipment.

These factors are expected to drive the segment. The apparatus & plants segment is projected to grow at a rapid CAGR over the forecast period due to its significant penetration in the bioprocessing space majorly driven by a variety of single-use bioreactors. For instance, single-use bioreactors are available from a working volume range of 15 mL and 250 mL, such as the Ambr 15 and 250 sold by Sartorius AG, to a working volume of 6000 L, such as the CSR 7500 SUB sold by ABEC. This allows the end-users to easily scale products right from the stage of clone selection and benchtop production to harvesting high-volume yields of biologics. As a result, the availability of a broad range of options for apparatus & plants for bioprocessing is anticipated to drive the segment.

Workflow Insights

The upstream bioprocessing segment held the largest market share of 57.9% in 2022. This can be attributed to the continuous developments and advancements in technologies for upstream bioprocessing. For instance, advanced products, such as Ambr 15 micro-bioreactor system by Sartorius AG, are offering high-throughput upstream process development as well as efficient cell culture processing and media & feed optimization with automated experimental setup and sampling. These solutions can reduce the time taken for upstream bioprocessing operations and are anticipated to boost segment growth. The fermentation segment is expected to register the second-fastest CAGR over the forecast period.

The growth can be attributed to the launch of several innovative fermentation offerings that provide optimum conditions for bioprocessing reactions. For instance, the HyPerforma Enhanced S.U.F by Thermo Fisher Scientific, Inc. delivers optimal oxygen mass transfers and temperature control to the culture by increasing the turbine impellers and cooling jacket surface areas, respectively. Furthermore, companies like Cytiva are also involved in bringing single-use fermentation solutions for their end-users, such as the Xcellerex XDR MO, a stirred tank system with powerful mixing, efficient temperature control, and high oxygen transfer capacities for microbial cell culture. Significant innovations like these are likely to aid in revenue generation in this segment.

End-use Insights

The biopharmaceutical manufacturers dominated the market and accounted for the highest share of 58.1% in 2022. An increase in the commercial success of biologics in recent years and a rise in contract manufacturing/research services have led to the high growth of the segment. CROs and CMOs can offer several benefits in bioprocessing operations, such as scalability, flexibility, decreased internal infrastructure requirements, and dedicated supply channels. These advantages are fueling the adoption of contract services and are anticipated to positively affect the industry growth in the near future. Academic & clinical research institutes are expected to grow at the fastest CAGR of 16.37% during 2023-2030.

The availability of benchtop scale bioprocessing equipment and technological progress in single-use systems has accelerated the adoption of such technologies in academic and research institutes. For instance, institutes like the NIBRT (National Institute for Bioprocessing Research), in Ireland offer contract research services for biologics, while also conducting workshops and training for single-use technologies. Furthermore, the involvement of academic institutes and scientific communities in developing new biologics, such as cell & gene therapies and vector production, is likely to increase the implementation of single-use systems due to its cost reduction and flexibility benefits.

Regional Insights

North America held the largest revenue share of more than 34.2% in 2022, which can be attributed to the presence of an established pharmaceutical and biomanufacturing industry in the region as well as a high extent of R&D activities. Similarly, the demand for single-use bioprocessing equipment is also driven by an increasing focus on vaccine production to aid in disease prevention measures in the region. Moreover, the presence of the Bio-process System Alliance (BPSA) in North America, which aims at advancing the adoption of single-use technologies, is expected to further drive the sales of disposable systems in the region.

The Asia Pacific region is expected to grow at the fastest rate of 16.71% over the forecast period. The region’s growing bioprocessing market has resulted in multiple investments from several global companies. These investments assist to serve the key companies to create a regional presence and take advantage of the untapped avenues. Furthermore, the increasing interest of contract service providers to develop their base in Asia Pacific, coupled with the trend of implementation of disposables in CMOs, acts as a catalyst for continued investments by local as well as global companies. For instance, in September 2021, Singapore witnessed the expansion of Lonza’s drug development facility. The CDMO enhanced its capacity to support the growing manufacturing needs in the region.

Key Companies & Market Share Insights

The market is witnessing several strategic initiatives adopted by key players to maintain their industry presence. For instance, in April 2022, Merck KGaA announced an investment of approximately USD 105 million to accelerate its single-use manufacturing in China. Some of the key companies operating in the global single-use bioprocessing market include:

• Sartorius AG

• Danaher Corp.

• Thermo Fisher Scientific, Inc.

• Merck KGaA

• Avantor, Inc.

• Eppendorf SE

• Corning Inc.

• Boehringer Ingelheim International GmbH

• Lonza

• Infors AG

• PBS Biotech, Inc.

• Entegris, Inc.

• Kuhner AG

• Meissner Filtration Products, Inc.

• Rentschler Biopharma SE

Single-use Bioprocessing Market Report Scope

Global Single-use Bioprocessing Market Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For the purpose of this study, Grand View Research has segmented the global single-use bioprocessing market report on the basis of product, workflow, end-use, and region:

• Product Outlook (Revenue, USD Million, 2018 - 2030)

  • Simple & Peripheral Elements

    • Tubing, Filters, Connectors, & Transfer Systems

    • Bags

    • Sampling Systems

    • Probes & Sensors

      • pH Sensor

      • Oxygen Sensor

      • Pressure Sensors

      • Temperature Sensors

      • Conductivity Sensors

      • Flow Sensors

      • Others

    • Others

  • Apparatus & Plants

    • Bioreactors

      • Upto 1000L

      • Above 1000L to 2000L

      • Above 2000L

    • Mixing, Storage, & Filling Systems 

    • Filtration System

    • Chromatography Systems

    • Pumps

    • Others

  • Work Equipment

    • Cell Culture System

    • Syringes

    • Others

• Workflow Outlook (Revenue, USD Million, 2018 - 2030)

  • Upstream Bioprocessing

  • Fermentation

  • Downstream Bioprocessing

• End-use Outlook (Revenue, USD Million, 2018 - 2030)

  • Biopharmaceutical Manufacturers

    • CMOs & CROs

    • In-house Manufacturers

  • Academic & Clinical Research Institutes

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

  • U.S.

  • Canada

  • Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

  • Asia Pacific

  • Japan

  • China

  • India

  • South Korea

  • Australia

  • Thailand

  • Latin America

  • Brazil

  • Mexico

  • Argentina

  • Middle East and Africa (MEA)

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait